SHILPA MEDICARE LTD. - 530549 - Intimation Under 31A Of The SEBI (LODR) Regulations, 2015 For Reclassification From 'Promoter/Promoter Group' To 'Public'
Intimation pursuant to reg 31A of SEBI (LODR) 2015 for reclassification from promoter/promoter group to public SHILPA MEDICARE LTD. - 530549 - Outcome Of The Board Meeting
Un-Audited Financial results for the quarter and half year ended 30 September 2023 SHILPA MEDICARE LTD. - 530549 - Announcement Under Regulation 30 Of SEBI (LODR) 2015
USFDA Inspection of Shilpa Medicare Limited Unit 4, Jedcherla, Telangana. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q2 Conference call for investors & analysts is scheduled on Saturday, 11 November 2023 at 11:00 AM IST SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q2 Conference call for investors & Analysts is scheduled on 11 November 2023 at 11:00 IST SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting To Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Ended 30Th September,2023
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 ,inter alia, to consider and approve The meeting of Board of Directors of the Company is scheduled on Friday, 10 November 2023 to inter alia consider the Un-audited financial results for the quarter & half year ended 30 September 2023.
Shilpa Medicare shares up 2% on acquiring US-based Pilnova Pharma
The share touched a 52-week high of Rs 384.70 and a 52-week low of Rs 222.40 on 31 August, 2023 and 28 March, 2023, respectively. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Acquisition
Acquisition of Pilnova Pharma Inc - A Wholly owned Subsidiary SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Draft Scheme of Amalgamation between Shilpa Medicare limited & Shilpa Therapeutics Private Limited being a wholly owned Subsidiary Company SHILPA MEDICARE LTD. - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 26, 2023 for Deepak Kumar Innani